VBI Vaccines and Brii Biosciences expand Hepatitis B partnership to address prevention and treatment

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

VBI Vaccines recently announced the expansion of its hepatitis B (HBV) partnership with Brii Biosciences. This is a step towards combatting HBV by making improvements in preventing and treating patients with HBV. 

Adam Buckley, VBI's Senior Vice President, Business Development, is a member of the OBIO® Board of Directors.

Arsheen Kaur
Previous

BDC Thrive Lab launches $35m co-investment phase
Next

Epineuron announces launch of FDA clinical trial for bioelectronic therapy for nerve regeneration